Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 12.10
NONOF's Cash to Debt is ranked lower than
57% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. NONOF: 12.10 )
Ranked among companies with meaningful Cash to Debt only.
NONOF' s 10-Year Cash to Debt Range
Min: 0.29   Max: N/A
Current: 12.1

Equity to Asset 0.42
NONOF's Equity to Asset is ranked lower than
75% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NONOF: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
NONOF' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.73
Current: 0.42

0.42
0.73
Interest Coverage 884.41
NONOF's Interest Coverage is ranked lower than
82% of the 380 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NONOF: 884.41 )
Ranked among companies with meaningful Interest Coverage only.
NONOF' s 10-Year Interest Coverage Range
Min: 5.69   Max: 884.41
Current: 884.41

5.69
884.41
F-Score: 8
Z-Score: 17.15
M-Score: -2.37
WACC vs ROIC
12.54%
109.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 40.51
NONOF's Operating margin (%) is ranked higher than
95% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. NONOF: 40.51 )
Ranked among companies with meaningful Operating margin (%) only.
NONOF' s 10-Year Operating margin (%) Range
Min: 10.5   Max: 38.84
Current: 40.51

10.5
38.84
Net-margin (%) 31.92
NONOF's Net-margin (%) is ranked higher than
93% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. NONOF: 31.92 )
Ranked among companies with meaningful Net-margin (%) only.
NONOF' s 10-Year Net-margin (%) Range
Min: 12.09   Max: 30.13
Current: 31.92

12.09
30.13
ROE (%) 82.77
NONOF's ROE (%) is ranked higher than
98% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.55 vs. NONOF: 82.77 )
Ranked among companies with meaningful ROE (%) only.
NONOF' s 10-Year ROE (%) Range
Min: 13   Max: 63.92
Current: 82.77

13
63.92
ROA (%) 42.38
NONOF's ROA (%) is ranked higher than
98% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. NONOF: 42.38 )
Ranked among companies with meaningful ROA (%) only.
NONOF' s 10-Year ROA (%) Range
Min: 9.1   Max: 37.03
Current: 42.38

9.1
37.03
ROC (Joel Greenblatt) (%) 156.29
NONOF's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. NONOF: 156.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NONOF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.89   Max: 141.95
Current: 156.29

6.89
141.95
Revenue Growth (3Y)(%) 13.20
NONOF's Revenue Growth (3Y)(%) is ranked higher than
69% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. NONOF: 13.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NONOF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -46.2   Max: 127.6
Current: 13.2

-46.2
127.6
EBITDA Growth (3Y)(%) 16.70
NONOF's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. NONOF: 16.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NONOF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -44.6   Max: 130.7
Current: 16.7

-44.6
130.7
EPS Growth (3Y)(%) 18.80
NONOF's EPS Growth (3Y)(%) is ranked higher than
76% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. NONOF: 18.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NONOF' s 10-Year EPS Growth (3Y)(%) Range
Min: 5.9   Max: 37.2
Current: 18.8

5.9
37.2
» NONOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NONOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 34.00
NONOF's P/E(ttm) is ranked higher than
57% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 40.20 vs. NONOF: 34.00 )
Ranked among companies with meaningful P/E(ttm) only.
NONOF' s 10-Year P/E(ttm) Range
Min: 12.13   Max: 34.43
Current: 34

12.13
34.43
Forward P/E 25.84
NONOF's Forward P/E is ranked lower than
64% of the 311 Companies
in the Global Biotechnology industry.

( Industry Median: 21.05 vs. NONOF: 25.84 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 34.00
NONOF's PE(NRI) is ranked higher than
56% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. NONOF: 34.00 )
Ranked among companies with meaningful PE(NRI) only.
NONOF' s 10-Year PE(NRI) Range
Min: 12.03   Max: 34.44
Current: 34

12.03
34.44
P/B 32.00
NONOF's P/B is ranked lower than
100% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NONOF: 32.00 )
Ranked among companies with meaningful P/B only.
NONOF' s 10-Year P/B Range
Min: 3.5   Max: 32.45
Current: 32

3.5
32.45
P/S 10.93
NONOF's P/S is ranked higher than
53% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.17 vs. NONOF: 10.93 )
Ranked among companies with meaningful P/S only.
NONOF' s 10-Year P/S Range
Min: 2.81   Max: 11.04
Current: 10.93

2.81
11.04
PFCF 37.10
NONOF's PFCF is ranked lower than
52% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. NONOF: 37.10 )
Ranked among companies with meaningful PFCF only.
NONOF' s 10-Year PFCF Range
Min: 12.07   Max: 47.01
Current: 37.1

12.07
47.01
POCF 32.12
NONOF's POCF is ranked lower than
51% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 31.25 vs. NONOF: 32.12 )
Ranked among companies with meaningful POCF only.
NONOF' s 10-Year POCF Range
Min: 7.96   Max: 32.56
Current: 32.12

7.96
32.56
EV-to-EBIT 26.93
NONOF's EV-to-EBIT is ranked higher than
58% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 30.27 vs. NONOF: 26.93 )
Ranked among companies with meaningful EV-to-EBIT only.
NONOF' s 10-Year EV-to-EBIT Range
Min: 9.1   Max: 27.3
Current: 26.93

9.1
27.3
PEG 1.73
NONOF's PEG is ranked higher than
63% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. NONOF: 1.73 )
Ranked among companies with meaningful PEG only.
NONOF' s 10-Year PEG Range
Min: 0.54   Max: 1.65
Current: 1.73

0.54
1.65
Shiller P/E 50.50
NONOF's Shiller P/E is ranked lower than
55% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. NONOF: 50.50 )
Ranked among companies with meaningful Shiller P/E only.
NONOF' s 10-Year Shiller P/E Range
Min: 18.94   Max: 51.34
Current: 50.5

18.94
51.34
Current Ratio 1.04
NONOF's Current Ratio is ranked lower than
87% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. NONOF: 1.04 )
Ranked among companies with meaningful Current Ratio only.
NONOF' s 10-Year Current Ratio Range
Min: 1.04   Max: 2.45
Current: 1.04

1.04
2.45
Quick Ratio 0.74
NONOF's Quick Ratio is ranked lower than
88% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. NONOF: 0.74 )
Ranked among companies with meaningful Quick Ratio only.
NONOF' s 10-Year Quick Ratio Range
Min: 0.74   Max: 1.91
Current: 0.74

0.74
1.91
Days Inventory 272.73
NONOF's Days Inventory is ranked lower than
84% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. NONOF: 272.73 )
Ranked among companies with meaningful Days Inventory only.
NONOF' s 10-Year Days Inventory Range
Min: 201.98   Max: 417.53
Current: 272.73

201.98
417.53
Days Sales Outstanding 57.08
NONOF's Days Sales Outstanding is ranked higher than
54% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. NONOF: 57.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
NONOF' s 10-Year Days Sales Outstanding Range
Min: 45.09   Max: 152.61
Current: 57.08

45.09
152.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.29
NONOF's Dividend Yield is ranked higher than
62% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. NONOF: 1.29 )
Ranked among companies with meaningful Dividend Yield only.
NONOF' s 10-Year Dividend Yield Range
Min: 0.79   Max: 2.47
Current: 1.29

0.79
2.47
Dividend Payout 0.44
NONOF's Dividend Payout is ranked lower than
67% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 0.39 vs. NONOF: 0.44 )
Ranked among companies with meaningful Dividend Payout only.
NONOF' s 10-Year Dividend Payout Range
Min: 0.51   Max: 1.85
Current: 0.44

0.51
1.85
Dividend growth (3y) 46.20
NONOF's Dividend growth (3y) is ranked higher than
93% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. NONOF: 46.20 )
Ranked among companies with meaningful Dividend growth (3y) only.
NONOF' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 49.4
Current: 46.2

0
49.4
Yield on cost (5-Year) 6.16
NONOF's Yield on cost (5-Year) is ranked higher than
93% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.28 vs. NONOF: 6.16 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NONOF' s 10-Year Yield on cost (5-Year) Range
Min: 3.74   Max: 11.7
Current: 6.16

3.74
11.7
Share Buyback Rate 2.60
NONOF's Share Buyback Rate is ranked higher than
96% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. NONOF: 2.60 )
Ranked among companies with meaningful Share Buyback Rate only.
NONOF' s 10-Year Share Buyback Rate Range
Min: 49.1   Max: -92.3
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 26.60
NONOF's Price/Tangible Book is ranked lower than
101% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. NONOF: 26.60 )
Ranked among companies with meaningful Price/Tangible Book only.
NONOF' s 10-Year Price/Tangible Book Range
Min: 3.15   Max: 17.72
Current: 26.6

3.15
17.72
Price/DCF (Projected) 4.80
NONOF's Price/DCF (Projected) is ranked lower than
55% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NONOF: 4.80 )
Ranked among companies with meaningful Price/DCF (Projected) only.
NONOF' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 23.73
Current: 4.8

1.3
23.73
Price/Median PS Value 2.40
NONOF's Price/Median PS Value is ranked lower than
69% of the 784 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. NONOF: 2.40 )
Ranked among companies with meaningful Price/Median PS Value only.
NONOF' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 2.13
Current: 2.4

0.16
2.13
Price/Peter Lynch Fair Value 1.90
NONOF's Price/Peter Lynch Fair Value is ranked higher than
67% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.30 vs. NONOF: 1.90 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NONOF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.07   Max: 1.49
Current: 1.9

0.07
1.49
Price/Graham Number 6.80
NONOF's Price/Graham Number is ranked lower than
71% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. NONOF: 6.80 )
Ranked among companies with meaningful Price/Graham Number only.
NONOF' s 10-Year Price/Graham Number Range
Min: 1.58   Max: 6.86
Current: 6.8

1.58
6.86
Earnings Yield (Greenblatt) 3.70
NONOF's Earnings Yield (Greenblatt) is ranked higher than
90% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. NONOF: 3.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
NONOF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.7   Max: 11
Current: 3.7

3.7
11
Forward Rate of Return (Yacktman) 23.85
NONOF's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 14.93 vs. NONOF: 23.85 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
NONOF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.7   Max: 36.1
Current: 23.85

1.7
36.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMGN, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:NVO.USA, 0QIU.UK, NOVO B.Denmark, NOVA.Germany, NOVC.Germany, NOVOB.Switzerland,
Novo-Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was approved in the United States in December 2014. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. On December 23, 2014, the GLP-1 agonist liraglutide was approved in the United States in a 3 mg dose for weight management. The trade name for this product will be Saxenda and launch is planned for the first half of 2015. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. In 2014 the Company announced that all activities within inflammation will be discontinued. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the major European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Algeria, Turkey, Australia, India, Argentina, Brazil and Russia.
» More Articles for NONOF

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Additional Changes to the Nintai Portfolio Apr 08 2015 
Probability and Magnitude in Investing Apr 02 2015 
Nintai Returns: Q1 2015 Apr 01 2015 
These High-Quality European Dividend Payers Could Benefit From A Rising Dollar Mar 18 2015 
To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
Guru Stocks at 52-Week Lows: BABA, NVO, PCLN, ING, EMR Feb 09 2015 
Examining The Three Largest Guru Portfolios Oct 24 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 

More From Other Websites
Hemophilia market will see production rise as Novo Nordisk invest US$225mn in new plant May 25 2015
Novo Nordisk's Saxenda Delays Onset of Type II Diabetes - Analyst Blog May 25 2015
Novo Nordisk, Baxter clash over haemophilia drug patent May 20 2015
Novo Nordisk rejects Baxter patent claim over Novoeight May 20 2015
Novo Nordisk weighs diabetes drug's use in fatty liver disease May 18 2015
Billionaire Jim Simons’ Top Holdings: Amazon.com Inc. (AMZN), Colgate-Palmolive Company and More May 17 2015
UnitedHealth Group (UNH), Novo Nordisk (NVO), Johnson & Johnson (JNJ): Cheapest Healthcare Stocks... May 14 2015
Hot Drugs Show Sharp Price Hikes in Shadow Market May 06 2015
Novo Nordisk (NVO) Beats on Q1 Earnings, Updates Outlook - Analyst Blog May 04 2015
Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015
Gilead EPS Spikes On Harvoni Drug, Latest HCV Fighter Apr 30 2015
We've successfully hedged currencies: Novo Nordisk CFO Apr 30 2015
Economic Sentiment up in the Eurozone: EWG up 0.88%, FEZ up 0.46% Apr 22 2015
Novo launches Saxenda in US, sees more launches in 2015 Apr 22 2015
Novo Nordisk says Saxenda obesity drug to cost $1,068 per month Apr 22 2015
3 Large-Cap Pharmaceutical Companies to Invest in Right Now Apr 22 2015
BUZZ-L'Oreal: is it worth it? Apr 13 2015
FDA accepts Novo Nordisk's resubmitted application for insulin drug Apr 07 2015
FDA Urged to Fine Drugmakers Over Ads Apr 01 2015
The Best and Worst Medalists of 2015's First Quarter Mar 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK